{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:16:55Z","timestamp":1794449815675,"version":"4.9.1"},"reference-count":17,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic graft-versus-host disease (GvHD) treatment response is assessed using National Institutes of Health (NIH) Consensus Criteria in clinical trials, and by clinician assessment in routine practice. Patient-reported treatment response is central to the experience of chronic GvHD manifestations as well as treatment benefit and toxicity, but how they correlate with clinician- or NIH-responses has not been well-studied. We aimed to characterize 6-month patientreported response, determine associated chronic GvHD baseline organ features and changes, and evaluate which patientreported quality of life and chronic GvHD symptom burden measures correlated with patient-reported response. From two nationally representative Chronic GVHD Consortium prospective observational studies, 382 subjects were included in this analysis. Patient and clinician responses were categorized as improved (completely gone, very much better, moderately better, a little better) versus not improved (about the same, a little worse, moderately worse, very much worse). At six months, 270 (71%) patients perceived chronic GvHD improvement, while 112 (29%) perceived no improvement. Patient-reported response had limited correlation with either clinician-reported (kappa 0.37) or NIH chronic GvHD response criteria (kappa 0.18). Notably, patient-reported response at six months was significantly associated with subsequent failure-free survival. In multivariate analysis, NIH responses in eye, mouth, and lung had significant association with 6-month patient-reported response, as well as a change in Short Form 36 general health and role physical domains and Lee Symptom Score skin and eye changes. Based on these findings, patient-reported responses should be considered as an important complementary endpoint in chronic GvHD clinical trials and drug development.<\/jats:p>","DOI":"10.3324\/haematol.2023.282734","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T15:22:27Z","timestamp":1685028147000},"page":"143-150","source":"Crossref","is-referenced-by-count":12,"title":["Patient-reported treatment response in chronic graft-&lt;i&gt;versus&lt;\/i&gt;-host disease"],"prefix":"10.3324","volume":"109","author":[{"given":"Annie","family":"Im","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Onstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin M.","family":"Alousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"56152","doi-asserted-by":"crossref","unstructured":"Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003; 9(4):215-233.","DOI":"10.1053\/bbmt.2003.50026"},{"key":"56153","doi-asserted-by":"crossref","unstructured":"Arai S, Arora M, Wang T. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015; 21(2):266-274.","DOI":"10.1016\/j.bbmt.2014.10.021"},{"key":"56154","doi-asserted-by":"crossref","unstructured":"Martin PJ, Weisdorf D, Przepiorka D. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006; 12(5):491-505.","DOI":"10.1016\/j.bbmt.2006.03.004"},{"key":"56155","doi-asserted-by":"crossref","unstructured":"Filipovich AH, Weisdorf D, Pavletic S. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-956.","DOI":"10.1016\/j.bbmt.2005.10.001"},{"key":"56156","doi-asserted-by":"crossref","unstructured":"Pavletic SZ, Martin P, Lee SJ. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006; 12(3):252-266.","DOI":"10.1016\/j.bbmt.2005.10.001"},{"key":"56157","doi-asserted-by":"crossref","unstructured":"Lee SJ, Wolff D, Kitko C. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015; 21(6):984-999.","DOI":"10.1016\/j.bbmt.2015.02.025"},{"key":"56158","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015; 21(3):389-401.","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"56159","doi-asserted-by":"crossref","unstructured":"Palmer J, Chai X, Pidala J. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood. 2016; 127(1):160-166.","DOI":"10.1182\/blood-2015-08-662874"},{"key":"56160","doi-asserted-by":"crossref","unstructured":"Martin PJ, Storer BE, Palmer J. Organ changes associated with provider-assessed responses in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2019; 25(9):1869-1874.","DOI":"10.1016\/j.bbmt.2019.05.008"},{"key":"56161","doi-asserted-by":"crossref","unstructured":"Palmer JM, Lee SJ, Chai X. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012; 18(11):1649-1655.","DOI":"10.1016\/j.bbmt.2012.05.005"},{"key":"56162","doi-asserted-by":"crossref","unstructured":"Inamoto Y, Martin PJ, Chai X. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012; 18(10):1517-1524.","DOI":"10.1016\/j.bbmt.2012.05.016"},{"key":"56163","doi-asserted-by":"crossref","unstructured":"Pidala J, Kurland B, Chai X. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011; 117(17):4651-4657.","DOI":"10.1182\/blood-2010-11-319509"},{"key":"56164","doi-asserted-by":"crossref","unstructured":"Chronic GC. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant. 2011; 17(8):1114-1120.","DOI":"10.1016\/j.bbmt.2011.05.007"},{"key":"56165","doi-asserted-by":"crossref","unstructured":"Lee SJ, Hamilton BK, Pidala J. The Chronic GVHD Consortium. Design and patient characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. Biol Blood Marrow Transplant. 2018; 24(8):1727-1732.","DOI":"10.1016\/j.bbmt.2018.02.010"},{"key":"56166","doi-asserted-by":"crossref","unstructured":"Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444-452.","DOI":"10.1053\/bbmt.2002.v8.pm12234170"},{"key":"56167","doi-asserted-by":"crossref","unstructured":"Inamoto Y, Flowers ME, Sandmaier BM. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014; 124(8):1363-1371.","DOI":"10.1182\/blood-2014-03-563544"},{"key":"56168","doi-asserted-by":"crossref","unstructured":"Inamoto Y, Storer BE, Lee SJ. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013; 121(12):2340-2346.","DOI":"10.1182\/blood-2012-11-465583"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282734\/75629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282734\/76431","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11094\/75629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:08Z","timestamp":1794045848000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282734","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,25]]}}}